Scarica l'app Stockscreener
5.82
13.26%
-0.89
Dopo l'orario di chiusura:
5.93
0.11
+1.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.71
Aprire:
$6.65
Volume 24 ore:
2.87M
Relative Volume:
2.16
Capitalizzazione di mercato:
$624.05M
Reddito:
$6.17M
Utile/perdita netta:
$-191.78M
Rapporto P/E:
-2.99
EPS:
-1.9465
Flusso di cassa netto:
$-172.86M
1 W Prestazione:
-15.90%
1M Prestazione:
-33.10%
6M Prestazione:
-30.63%
1 anno Prestazione:
-3.16%
Intervallo 1D:
$5.70
$6.65
Intervallo di 1 settimana:
$5.70
$7.045
Portata 52W:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Nome
Solid Biosciences Inc
Settore
Industria
Telefono
617-337-4680
Indirizzo
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.82 | 624.05M | 6.17M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-08-21 | Ripresa | Truist | Buy |
| 2026-03-20 | Iniziato | Guggenheim | Buy |
| 2025-12-04 | Iniziato | Needham | Buy |
| 2025-06-26 | Iniziato | Citigroup | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-13 | Iniziato | Wedbush | Outperform |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-15 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | William Blair | Outperform |
| 2024-03-15 | Iniziato | Citigroup | Buy |
| 2024-03-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-05-27 | Iniziato | Jefferies | Buy |
| 2021-03-16 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Iniziato | Evercore ISI | Outperform |
| 2019-08-29 | Downgrade | Citigroup | Neutral → Sell |
| 2019-08-19 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Downgrade | Goldman | Neutral → Sell |
| 2019-02-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-02-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Iniziato | Citigroup | Sell |
| 2018-09-06 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Form 4 Solid Biosciences LLC For: 11 October By Investing.com - Investing.com Canada
A director converts a stock grant and holds 141,585 Solid Biosciences (SLDB) shares directly. - Stock Titan
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB) - Seeking Alpha
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Solid Biosciences stock gains on fresh analyst upgrades and DMD outlook - AD HOC NEWS
Solid Biosciences Inc.Common Stock (Nasdaq:SLDB) Detailed Stock Data - The Chronicle-Journal
Solid Biosciences wins new Outperform at RBC on DMD opportunity - Seeking Alpha
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - kalkine.com.au
Solid Biosciences at Citi summit: FDA tests loom for gene therapy push - Investing.com Canada
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com India
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com Canada
SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025 - TradingView
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Solid Biosciences to Participate at Upcoming Investor Conferences - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
Cantor raises Solid Biosciences stock price target on gene therapy - Investing.com
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com Canada
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com UK
Cantor Fitzgerald Maintains Solid Biosciences(SLDB.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SLDB Maintained by Truist Securities -- Price Target Raised to $20 - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7%Time to Sell? - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab - Traders Union
Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits - Stock Titan
Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares - Stock Titan
Solid Biosciences (SLDB) Holds Steady Near $9.09 as Gene Therapy Sector Watches Key LevelsVolume Weighted Price - vinanet.vn
HC Wainwright Has Positive Estimate for SLDB Q3 Earnings - MarketBeat
Form 8K Solid Biosciences LLC For: 6 August By Investing.com - Investing.com Nigeria
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com India
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Canada
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com UK
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Solid Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside - TradingView
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Solid Biosciences files prospectus for up to $200 million at-the-market stock offering - Bitget
Solid Biosciences (SLDB) Eyes Key Clinical Milestones Amid High Valuation on Price-to-Sales Basis - GuruFocus
Solid Biosciences Inc Azioni (SLDB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Solid Biosciences Inc Azioni (SLDB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hanrahan Jessie | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
4,134 |
24,074 |
0 |
| Ganot Ilan | Director |
Feb 18 '26 |
Sale |
5.82 |
2,658 |
15,478 |
27,474 |
| Herzich Paul | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
3,616 |
21,057 |
0 |
| Ganot Ilan | Director |
Feb 18 '26 |
Proposed Sale |
5.92 |
2,658 |
15,748 |
0 |
| Brooks Gabriel | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
5,563 |
32,395 |
0 |
| Herzich Paul | Chief Technology Officer |
Feb 18 '26 |
Sale |
5.82 |
3,616 |
21,057 |
72,638 |
| Howton David T | Chief Operating Officer |
Feb 18 '26 |
Sale |
5.82 |
7,469 |
43,494 |
105,077 |
| Howton David T | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
7,469 |
43,494 |
0 |
| Tan Kevin | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
5,404 |
31,469 |
0 |
| Tan Kevin | CFO & Treasurer |
Feb 18 '26 |
Sale |
5.82 |
5,404 |
31,469 |
99,422 |
4.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):